Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS
· Delayed Price · Currency is USD
27.00
-0.31 (-1.14%)
Dec 23, 2024, 4:00 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 446.55B JPY in the quarter ending September 30, 2024, with 18.92% growth. This brings the company's revenue in the last twelve months to 1.76T, up 25.84% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,758.07B JPY
Revenue Growth
+25.84%
P/S Ratio
n/a
Revenue / Employee
93.88M JPY
Employees
18,726
Market Cap
52.62B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Daiichi Sankyo Company News
- 5 weeks ago - England Pricing Talks Fail on Astra, Daiichi Breast Cancer Drug - BNN Bloomberg
- 5 weeks ago - Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS - Business Wire
- 6 weeks ago - ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product - Benzinga
- 7 weeks ago - Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well - CNBC
- 7 weeks ago - Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals - BNN Bloomberg
- 2 months ago - Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ... - GuruFocus